Novo Nordisk's investor relations highlighted that the launch of its oral semaglutide is progressing with dose escalation patterns differing from its injectable forms. Despite improved data capture at 65%, 90% of prescriptions are still paid out-of-pocket rather than through insurance. The injectable market faces intense competition, with Canadian prices discounted 40-65% and compounded semaglutide supply peaking but remaining significant with 1.5 million patients still using it. Deutsche Bank maintains a hold rating on Novo Nordisk, reflecting balanced risks amid pricing pressures and pipeline developments.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
